Additional Study Information: The purpose of this research study is to find out if a drug called capmatinib is safe and effective (can help people) in people who have non-small cell lung cancer (NSCLC) who are also eligible for surgery. Capmatinib is an oral drug that targets particular processes, which may not be working properly in the cancer cells (dysregulation) in the body. Prior to surgery, participants will receive two cycles (a treatment cycle is 4 weeks long) of capmatinib. After the two cycles are complete, participants will undergo surgery to remove their cancer. After surgery, the Study Doctor may or may not prescribe chemotherapy before starting capmatinib treatment again.